CLVS Key Stats
- Pre-Open Stock Movers 12/04: (OCLS) (PLUG) (OMED) Higher; (AMBI) (EXPR) (OVTI) Lower (more...) Street Insider Dec 4
- Clovis Oncology (CLVS) Prices 2M Share Offering at $57.50/sh Street Insider Dec 3
- Does Sanofi Need to Turn to M&A to Bulk Up Its Oncology Assets? Fool Dec 3
- Pre-Open Stock Movers 12/03: (OMED) (UNIS) (AAPL) Higher; (KKD) (CNAT) (ECTE) Lower (more...) Street Insider Dec 3
- Streetinsider.com After-Hours Movers 12/02: (CNAT) (ASNA) (SCVL) Higher; (KKD) (GMAN) (TAXI) Lower Street Insider Dec 2
- Clovis Oncology Announces Proposed Secondary Offering of Shares of Common Stock by Selling Stockholders noodls Dec 2
- Clovis Oncology (CLVS) Announces 2M Common Secondary Offering Street Insider Dec 2
- Clovis files to sell 2M shares of common stock for holders Dec 2
- 3 Biotech Stocks That Soared on Tuesday Nov 27
- Opportunities in Lung Cancer Therapies Nov 23
CLVS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Clovis Oncology is up 266.7% over the last year vs S&P 500 Total Return up 30.02%, Biomarin Pharmaceutical up 44.01%, and AstraZeneca up 25.90%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for CLVS
Pro Report PDF for CLVS
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CLVS Pro Report PDF
Pro Strategies Featuring CLVS
Did Clovis Oncology make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Clovis Oncology Inc is a biopharmaceutical company. The Company is engaged in acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.